Cargando…

Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer

Background: Lung cancer has become the leading cause of cancer death for men and women. Most patients are diagnosed at an advanced stage when surgery is no longer a therapeutic option. At this stage, cytological samples are often the less invasive source for diagnosis and the determination of predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankel, Diane, Nanni, Isabelle, Ouafik, L’Houcine, Greillier, Laurent, Dutau, Hervé, Astoul, Philippe, Daniel, Laurent, Kaspi, Elise, Roll, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001120/
https://www.ncbi.nlm.nih.gov/pubmed/36899890
http://dx.doi.org/10.3390/cells12050754
_version_ 1784904055595728896
author Frankel, Diane
Nanni, Isabelle
Ouafik, L’Houcine
Greillier, Laurent
Dutau, Hervé
Astoul, Philippe
Daniel, Laurent
Kaspi, Elise
Roll, Patrice
author_facet Frankel, Diane
Nanni, Isabelle
Ouafik, L’Houcine
Greillier, Laurent
Dutau, Hervé
Astoul, Philippe
Daniel, Laurent
Kaspi, Elise
Roll, Patrice
author_sort Frankel, Diane
collection PubMed
description Background: Lung cancer has become the leading cause of cancer death for men and women. Most patients are diagnosed at an advanced stage when surgery is no longer a therapeutic option. At this stage, cytological samples are often the less invasive source for diagnosis and the determination of predictive markers. We assessed the ability of cytological samples to perform diagnosis, and to establish molecular profile and PD-L1 expression, which are essential for the therapeutic management of patients. Methods: We included 259 cytological samples with suspected tumor cells and assessed the ability to confirm the type of malignancy by immunocytochemistry. We summarized results of molecular testing by next generation sequencing (NGS) and PD-L1 expression from these samples. Finally, we analyzed the impact of these results in the patient management. Results: Among the 259 cytological samples, 189 concerned lung cancers. Of these, immunocytochemistry confirmed the diagnosis in 95%. Molecular testing by NGS was obtained in 93% of lung adenocarcinomas and non-small cell lung cancer. PD-L1 results were obtained in 75% of patients tested. The results obtained with cytological samples led to a therapeutic decision in 87% of patients. Conclusion: Cytological samples are obtained by minimally invasive procedures and can provide enough material for the diagnosis and therapeutic management in lung cancer patients.
format Online
Article
Text
id pubmed-10001120
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100011202023-03-11 Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer Frankel, Diane Nanni, Isabelle Ouafik, L’Houcine Greillier, Laurent Dutau, Hervé Astoul, Philippe Daniel, Laurent Kaspi, Elise Roll, Patrice Cells Communication Background: Lung cancer has become the leading cause of cancer death for men and women. Most patients are diagnosed at an advanced stage when surgery is no longer a therapeutic option. At this stage, cytological samples are often the less invasive source for diagnosis and the determination of predictive markers. We assessed the ability of cytological samples to perform diagnosis, and to establish molecular profile and PD-L1 expression, which are essential for the therapeutic management of patients. Methods: We included 259 cytological samples with suspected tumor cells and assessed the ability to confirm the type of malignancy by immunocytochemistry. We summarized results of molecular testing by next generation sequencing (NGS) and PD-L1 expression from these samples. Finally, we analyzed the impact of these results in the patient management. Results: Among the 259 cytological samples, 189 concerned lung cancers. Of these, immunocytochemistry confirmed the diagnosis in 95%. Molecular testing by NGS was obtained in 93% of lung adenocarcinomas and non-small cell lung cancer. PD-L1 results were obtained in 75% of patients tested. The results obtained with cytological samples led to a therapeutic decision in 87% of patients. Conclusion: Cytological samples are obtained by minimally invasive procedures and can provide enough material for the diagnosis and therapeutic management in lung cancer patients. MDPI 2023-02-27 /pmc/articles/PMC10001120/ /pubmed/36899890 http://dx.doi.org/10.3390/cells12050754 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Frankel, Diane
Nanni, Isabelle
Ouafik, L’Houcine
Greillier, Laurent
Dutau, Hervé
Astoul, Philippe
Daniel, Laurent
Kaspi, Elise
Roll, Patrice
Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer
title Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer
title_full Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer
title_fullStr Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer
title_full_unstemmed Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer
title_short Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer
title_sort cytological samples: an asset for the diagnosis and therapeutic management of patients with lung cancer
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001120/
https://www.ncbi.nlm.nih.gov/pubmed/36899890
http://dx.doi.org/10.3390/cells12050754
work_keys_str_mv AT frankeldiane cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer
AT nanniisabelle cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer
AT ouafiklhoucine cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer
AT greillierlaurent cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer
AT dutauherve cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer
AT astoulphilippe cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer
AT daniellaurent cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer
AT kaspielise cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer
AT rollpatrice cytologicalsamplesanassetforthediagnosisandtherapeuticmanagementofpatientswithlungcancer